Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ROS1 fusion |
| Therapy | Entrectinib |
| Indication/Tumor Type | central nervous system cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ROS1 fusion | central nervous system cancer | predicted - sensitive | Entrectinib | Clinical Study - Cohort | Actionable | In a combined analysis of 3 clinical trials (STARTRK-NG, TAPISTRY, STARTRK-2), Rozlytrek (entrectinib) treatment resulted in an objective response rate (ORR) of 65.0% (13/20, 3 complete (CR) and 10 partial (PR) responses) in pediatric patients (median age 7.5 yo) with solid tumors harboring ROS1 fusions, with median time to response of 1.87 mo, ORR was 75.0% (6/8, 2 CR, 4 PR) in patients with CNS tumors (PMID: 40086048; NCT02650401, NCT04589845, NCT02568267). | 40086048 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40086048) | Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions. | Full reference... |